CovidFranceV1, Main, Exploration, bibRecord, 001236

Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting.

Identifieur interne : 001236 ( Main/Exploration ); précédent : 001235; suivant : 001237

Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting.

Auteurs : Fran Robson [Royaume-Uni] ; Khadija Shahed Khan [Hong Kong] ; Thi Khanh Le [France] ; Clément Paris [France] ; Sinem Demirbag [Turquie] ; Peter Barfuss [France] ; Palma Rocchi [France] ; Wai-Lung Ng [Hong Kong]

Source :

Molecular cell [ 1097-4164 ] ; 2020.

RBID : pubmed:32853546

Descripteurs français

KwdFr :
- AMP (analogues et dérivés), AMP (composition chimique), AMP (usage thérapeutique), ARN viral (antagonistes et inhibiteurs), ARN viral (génétique), ARN viral (métabolisme), Alanine (analogues et dérivés), Alanine (composition chimique), Alanine (usage thérapeutique), Amides (composition chimique), Amides (usage thérapeutique), Antiviraux (composition chimique), Antiviraux (usage thérapeutique), Betacoronavirus (effets des médicaments et des substances chimiques), Betacoronavirus (génétique), Betacoronavirus (pathogénicité), Génome viral (MeSH), Humains (MeSH), Indice de gravité de la maladie (MeSH), Infections à coronavirus (traitement médicamenteux), Infections à coronavirus (virologie), Infections à coronavirus (épidémiologie), Mutation (MeSH), Pandémies (MeSH), Pneumopathie virale (traitement médicamenteux), Pneumopathie virale (virologie), Pneumopathie virale (épidémiologie), Protéines virales non structurales (antagonistes et inhibiteurs), Protéines virales non structurales (génétique), Protéines virales non structurales (métabolisme), Pyrazines (composition chimique), Pyrazines (usage thérapeutique), Ribonucléosides (composition chimique), Ribonucléosides (usage thérapeutique), Réplication virale (effets des médicaments et des substances chimiques), Thérapie moléculaire ciblée (méthodes), Transcription génétique (MeSH).
MESH :
- analogues et dérivés : AMP, Alanine.
- antagonistes et inhibiteurs : ARN viral, Protéines virales non structurales.
- composition chimique : AMP, Alanine, Amides, Antiviraux, Pyrazines, Ribonucléosides.
- effets des médicaments et des substances chimiques : Betacoronavirus, Réplication virale.
- génétique : ARN viral, Betacoronavirus, Protéines virales non structurales.
- métabolisme : ARN viral, Protéines virales non structurales.
- méthodes : Thérapie moléculaire ciblée.
- pathogénicité : Betacoronavirus.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : AMP, Alanine, Amides, Antiviraux, Pyrazines, Ribonucléosides.
- virologie : Infections à coronavirus, Pneumopathie virale.
- épidémiologie : Infections à coronavirus, Pneumopathie virale.
- Génome viral, Humains, Indice de gravité de la maladie, Mutation, Pandémies, Transcription génétique.

English descriptors

KwdEn :
- Adenosine Monophosphate (analogs & derivatives), Adenosine Monophosphate (chemistry), Adenosine Monophosphate (therapeutic use), Alanine (analogs & derivatives), Alanine (chemistry), Alanine (therapeutic use), Amides (chemistry), Amides (therapeutic use), Antiviral Agents (chemistry), Antiviral Agents (therapeutic use), Betacoronavirus (drug effects), Betacoronavirus (genetics), Betacoronavirus (pathogenicity), Coronavirus Infections (drug therapy), Coronavirus Infections (epidemiology), Coronavirus Infections (virology), Genome, Viral (MeSH), Humans (MeSH), Molecular Targeted Therapy (methods), Mutation (MeSH), Pandemics (MeSH), Pneumonia, Viral (drug therapy), Pneumonia, Viral (epidemiology), Pneumonia, Viral (virology), Pyrazines (chemistry), Pyrazines (therapeutic use), RNA, Viral (antagonists & inhibitors), RNA, Viral (genetics), RNA, Viral (metabolism), Ribonucleosides (chemistry), Ribonucleosides (therapeutic use), Severity of Illness Index (MeSH), Transcription, Genetic (MeSH), Viral Nonstructural Proteins (antagonists & inhibitors), Viral Nonstructural Proteins (genetics), Viral Nonstructural Proteins (metabolism), Virus Replication (drug effects).
MESH :
- chemical , analogs & derivatives : Adenosine Monophosphate, Alanine.
- chemical , antagonists & inhibitors : RNA, Viral, Viral Nonstructural Proteins.
- chemical , chemistry : Adenosine Monophosphate, Alanine, Amides, Antiviral Agents, Pyrazines, Ribonucleosides.
- chemical , genetics : RNA, Viral, Viral Nonstructural Proteins.
- chemical , metabolism : RNA, Viral, Viral Nonstructural Proteins.
- chemical , therapeutic use : Adenosine Monophosphate, Alanine, Amides, Antiviral Agents, Pyrazines, Ribonucleosides.
- drug effects : Betacoronavirus, Virus Replication.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- epidemiology : Coronavirus Infections, Pneumonia, Viral.
- genetics : Betacoronavirus.
- methods : Molecular Targeted Therapy.
- pathogenicity : Betacoronavirus.
- virology : Coronavirus Infections, Pneumonia, Viral.
- Genome, Viral, Humans, Mutation, Pandemics, Severity of Illness Index, Transcription, Genetic.

Abstract

The coronavirus disease 2019 (COVID-19) that is wreaking havoc on worldwide public health and economies has heightened awareness about the lack of effective antiviral treatments for human coronaviruses (CoVs). Many current antivirals, notably nucleoside analogs (NAs), exert their effect by incorporation into viral genomes and subsequent disruption of viral replication and fidelity. The development of anti-CoV drugs has long been hindered by the capacity of CoVs to proofread and remove mismatched nucleotides during genome replication and transcription. Here, we review the molecular basis of the CoV proofreading complex and evaluate its potential as a drug target. We also consider existing nucleoside analogs and novel genomic techniques as potential anti-CoV therapeutics that could be used individually or in combination to target the proofreading mechanism.

DOI: 10.1016/j.molcel.2020.07.027
PubMed: 32853546
PubMed Central: PMC7402271

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000338
to stream Main, to step Curation: 000338

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting.</title>
<author><name sortKey="Robson, Fran" sort="Robson, Fran" uniqKey="Robson F" first="Fran" last="Robson">Fran Robson</name>
<affiliation wicri:level="1"><nlm:affiliation>School of Biological Sciences, University of Bristol, Bristol, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>School of Biological Sciences, University of Bristol, Bristol</wicri:regionArea>
<wicri:noRegion>Bristol</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Khan, Khadija Shahed" sort="Khan, Khadija Shahed" uniqKey="Khan K" first="Khadija Shahed" last="Khan">Khadija Shahed Khan</name>
<affiliation wicri:level="4"><nlm:affiliation>School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong.</nlm:affiliation>
<country xml:lang="fr">Hong Kong</country>
<wicri:regionArea>School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong</wicri:regionArea>
<placeName><settlement type="city">Sha Tin</settlement>
</placeName>
<orgName type="university">Université chinoise de Hong Kong</orgName>
</affiliation>
</author>
<author><name sortKey="Le, Thi Khanh" sort="Le, Thi Khanh" uniqKey="Le T" first="Thi Khanh" last="Le">Thi Khanh Le</name>
<affiliation wicri:level="3"><nlm:affiliation>Life Science Department, University of Science and Technology of Hanoi (USTH), Hanoi, Vietnam; Centre de Recherche en Cancérologie de Marseille, CRCM, Inserm UMR1068, CNRS UMR7258, Aix-Marseille University U105, Institut Paoli-Calmettes, Marseille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Life Science Department, University of Science and Technology of Hanoi (USTH), Hanoi, Vietnam; Centre de Recherche en Cancérologie de Marseille, CRCM, Inserm UMR1068, CNRS UMR7258, Aix-Marseille University U105, Institut Paoli-Calmettes, Marseille</wicri:regionArea>
<placeName><region type="region">Provence-Alpes-Côte d'Azur</region>
<region type="old region">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Paris, Clement" sort="Paris, Clement" uniqKey="Paris C" first="Clément" last="Paris">Clément Paris</name>
<affiliation wicri:level="3"><nlm:affiliation>Centre de Recherche en Cancérologie de Marseille, CRCM, Inserm UMR1068, CNRS UMR7258, Aix-Marseille University U105, Institut Paoli-Calmettes, Marseille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Centre de Recherche en Cancérologie de Marseille, CRCM, Inserm UMR1068, CNRS UMR7258, Aix-Marseille University U105, Institut Paoli-Calmettes, Marseille</wicri:regionArea>
<placeName><region type="region">Provence-Alpes-Côte d'Azur</region>
<region type="old region">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Demirbag, Sinem" sort="Demirbag, Sinem" uniqKey="Demirbag S" first="Sinem" last="Demirbag">Sinem Demirbag</name>
<affiliation wicri:level="1"><nlm:affiliation>Faculty of Engineering and Natural Sciences, Sabanci University, İstanbul, Turkey.</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Faculty of Engineering and Natural Sciences, Sabanci University, İstanbul</wicri:regionArea>
<wicri:noRegion>İstanbul</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Barfuss, Peter" sort="Barfuss, Peter" uniqKey="Barfuss P" first="Peter" last="Barfuss">Peter Barfuss</name>
<affiliation wicri:level="3"><nlm:affiliation>Université Paris-Est, Cermics (ENPC), INRIA, 77455 Marne-la-Vallée, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Université Paris-Est, Cermics (ENPC), INRIA, 77455 Marne-la-Vallée</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Marne-la-Vallée</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rocchi, Palma" sort="Rocchi, Palma" uniqKey="Rocchi P" first="Palma" last="Rocchi">Palma Rocchi</name>
<affiliation wicri:level="3"><nlm:affiliation>Centre de Recherche en Cancérologie de Marseille, CRCM, Inserm UMR1068, CNRS UMR7258, Aix-Marseille University U105, Institut Paoli-Calmettes, Marseille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Centre de Recherche en Cancérologie de Marseille, CRCM, Inserm UMR1068, CNRS UMR7258, Aix-Marseille University U105, Institut Paoli-Calmettes, Marseille</wicri:regionArea>
<placeName><region type="region">Provence-Alpes-Côte d'Azur</region>
<region type="old region">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ng, Wai Lung" sort="Ng, Wai Lung" uniqKey="Ng W" first="Wai-Lung" last="Ng">Wai-Lung Ng</name>
<affiliation wicri:level="4"><nlm:affiliation>School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong. Electronic address: billyng@cuhk.edu.hk.</nlm:affiliation>
<country xml:lang="fr">Hong Kong</country>
<wicri:regionArea>School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong</wicri:regionArea>
<placeName><settlement type="city">Sha Tin</settlement>
</placeName>
<orgName type="university">Université chinoise de Hong Kong</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32853546</idno>
<idno type="pmid">32853546</idno>
<idno type="doi">10.1016/j.molcel.2020.07.027</idno>
<idno type="pmc">PMC7402271</idno>
<idno type="wicri:Area/Main/Corpus">000338</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000338</idno>
<idno type="wicri:Area/Main/Curation">000338</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000338</idno>
<idno type="wicri:Area/Main/Exploration">000338</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting.</title>
<author><name sortKey="Robson, Fran" sort="Robson, Fran" uniqKey="Robson F" first="Fran" last="Robson">Fran Robson</name>
<affiliation wicri:level="1"><nlm:affiliation>School of Biological Sciences, University of Bristol, Bristol, UK.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>School of Biological Sciences, University of Bristol, Bristol</wicri:regionArea>
<wicri:noRegion>Bristol</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Khan, Khadija Shahed" sort="Khan, Khadija Shahed" uniqKey="Khan K" first="Khadija Shahed" last="Khan">Khadija Shahed Khan</name>
<affiliation wicri:level="4"><nlm:affiliation>School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong.</nlm:affiliation>
<country xml:lang="fr">Hong Kong</country>
<wicri:regionArea>School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong</wicri:regionArea>
<placeName><settlement type="city">Sha Tin</settlement>
</placeName>
<orgName type="university">Université chinoise de Hong Kong</orgName>
</affiliation>
</author>
<author><name sortKey="Le, Thi Khanh" sort="Le, Thi Khanh" uniqKey="Le T" first="Thi Khanh" last="Le">Thi Khanh Le</name>
<affiliation wicri:level="3"><nlm:affiliation>Life Science Department, University of Science and Technology of Hanoi (USTH), Hanoi, Vietnam; Centre de Recherche en Cancérologie de Marseille, CRCM, Inserm UMR1068, CNRS UMR7258, Aix-Marseille University U105, Institut Paoli-Calmettes, Marseille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Life Science Department, University of Science and Technology of Hanoi (USTH), Hanoi, Vietnam; Centre de Recherche en Cancérologie de Marseille, CRCM, Inserm UMR1068, CNRS UMR7258, Aix-Marseille University U105, Institut Paoli-Calmettes, Marseille</wicri:regionArea>
<placeName><region type="region">Provence-Alpes-Côte d'Azur</region>
<region type="old region">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Paris, Clement" sort="Paris, Clement" uniqKey="Paris C" first="Clément" last="Paris">Clément Paris</name>
<affiliation wicri:level="3"><nlm:affiliation>Centre de Recherche en Cancérologie de Marseille, CRCM, Inserm UMR1068, CNRS UMR7258, Aix-Marseille University U105, Institut Paoli-Calmettes, Marseille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Centre de Recherche en Cancérologie de Marseille, CRCM, Inserm UMR1068, CNRS UMR7258, Aix-Marseille University U105, Institut Paoli-Calmettes, Marseille</wicri:regionArea>
<placeName><region type="region">Provence-Alpes-Côte d'Azur</region>
<region type="old region">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Demirbag, Sinem" sort="Demirbag, Sinem" uniqKey="Demirbag S" first="Sinem" last="Demirbag">Sinem Demirbag</name>
<affiliation wicri:level="1"><nlm:affiliation>Faculty of Engineering and Natural Sciences, Sabanci University, İstanbul, Turkey.</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Faculty of Engineering and Natural Sciences, Sabanci University, İstanbul</wicri:regionArea>
<wicri:noRegion>İstanbul</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Barfuss, Peter" sort="Barfuss, Peter" uniqKey="Barfuss P" first="Peter" last="Barfuss">Peter Barfuss</name>
<affiliation wicri:level="3"><nlm:affiliation>Université Paris-Est, Cermics (ENPC), INRIA, 77455 Marne-la-Vallée, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Université Paris-Est, Cermics (ENPC), INRIA, 77455 Marne-la-Vallée</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Marne-la-Vallée</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rocchi, Palma" sort="Rocchi, Palma" uniqKey="Rocchi P" first="Palma" last="Rocchi">Palma Rocchi</name>
<affiliation wicri:level="3"><nlm:affiliation>Centre de Recherche en Cancérologie de Marseille, CRCM, Inserm UMR1068, CNRS UMR7258, Aix-Marseille University U105, Institut Paoli-Calmettes, Marseille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Centre de Recherche en Cancérologie de Marseille, CRCM, Inserm UMR1068, CNRS UMR7258, Aix-Marseille University U105, Institut Paoli-Calmettes, Marseille</wicri:regionArea>
<placeName><region type="region">Provence-Alpes-Côte d'Azur</region>
<region type="old region">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Marseille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ng, Wai Lung" sort="Ng, Wai Lung" uniqKey="Ng W" first="Wai-Lung" last="Ng">Wai-Lung Ng</name>
<affiliation wicri:level="4"><nlm:affiliation>School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong. Electronic address: billyng@cuhk.edu.hk.</nlm:affiliation>
<country xml:lang="fr">Hong Kong</country>
<wicri:regionArea>School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong</wicri:regionArea>
<placeName><settlement type="city">Sha Tin</settlement>
</placeName>
<orgName type="university">Université chinoise de Hong Kong</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j">Molecular cell</title>
<idno type="eISSN">1097-4164</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenosine Monophosphate (analogs & derivatives)</term>
<term>Adenosine Monophosphate (chemistry)</term>
<term>Adenosine Monophosphate (therapeutic use)</term>
<term>Alanine (analogs & derivatives)</term>
<term>Alanine (chemistry)</term>
<term>Alanine (therapeutic use)</term>
<term>Amides (chemistry)</term>
<term>Amides (therapeutic use)</term>
<term>Antiviral Agents (chemistry)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Betacoronavirus (drug effects)</term>
<term>Betacoronavirus (genetics)</term>
<term>Betacoronavirus (pathogenicity)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Coronavirus Infections (epidemiology)</term>
<term>Coronavirus Infections (virology)</term>
<term>Genome, Viral (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Molecular Targeted Therapy (methods)</term>
<term>Mutation (MeSH)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>Pneumonia, Viral (epidemiology)</term>
<term>Pneumonia, Viral (virology)</term>
<term>Pyrazines (chemistry)</term>
<term>Pyrazines (therapeutic use)</term>
<term>RNA, Viral (antagonists & inhibitors)</term>
<term>RNA, Viral (genetics)</term>
<term>RNA, Viral (metabolism)</term>
<term>Ribonucleosides (chemistry)</term>
<term>Ribonucleosides (therapeutic use)</term>
<term>Severity of Illness Index (MeSH)</term>
<term>Transcription, Genetic (MeSH)</term>
<term>Viral Nonstructural Proteins (antagonists & inhibitors)</term>
<term>Viral Nonstructural Proteins (genetics)</term>
<term>Viral Nonstructural Proteins (metabolism)</term>
<term>Virus Replication (drug effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>AMP (analogues et dérivés)</term>
<term>AMP (composition chimique)</term>
<term>AMP (usage thérapeutique)</term>
<term>ARN viral (antagonistes et inhibiteurs)</term>
<term>ARN viral (génétique)</term>
<term>ARN viral (métabolisme)</term>
<term>Alanine (analogues et dérivés)</term>
<term>Alanine (composition chimique)</term>
<term>Alanine (usage thérapeutique)</term>
<term>Amides (composition chimique)</term>
<term>Amides (usage thérapeutique)</term>
<term>Antiviraux (composition chimique)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Betacoronavirus (effets des médicaments et des substances chimiques)</term>
<term>Betacoronavirus (génétique)</term>
<term>Betacoronavirus (pathogénicité)</term>
<term>Génome viral (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Indice de gravité de la maladie (MeSH)</term>
<term>Infections à coronavirus (traitement médicamenteux)</term>
<term>Infections à coronavirus (virologie)</term>
<term>Infections à coronavirus (épidémiologie)</term>
<term>Mutation (MeSH)</term>
<term>Pandémies (MeSH)</term>
<term>Pneumopathie virale (traitement médicamenteux)</term>
<term>Pneumopathie virale (virologie)</term>
<term>Pneumopathie virale (épidémiologie)</term>
<term>Protéines virales non structurales (antagonistes et inhibiteurs)</term>
<term>Protéines virales non structurales (génétique)</term>
<term>Protéines virales non structurales (métabolisme)</term>
<term>Pyrazines (composition chimique)</term>
<term>Pyrazines (usage thérapeutique)</term>
<term>Ribonucléosides (composition chimique)</term>
<term>Ribonucléosides (usage thérapeutique)</term>
<term>Réplication virale (effets des médicaments et des substances chimiques)</term>
<term>Thérapie moléculaire ciblée (méthodes)</term>
<term>Transcription génétique (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Adenosine Monophosphate</term>
<term>Alanine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>RNA, Viral</term>
<term>Viral Nonstructural Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Adenosine Monophosphate</term>
<term>Alanine</term>
<term>Amides</term>
<term>Antiviral Agents</term>
<term>Pyrazines</term>
<term>Ribonucleosides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>RNA, Viral</term>
<term>Viral Nonstructural Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>RNA, Viral</term>
<term>Viral Nonstructural Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adenosine Monophosphate</term>
<term>Alanine</term>
<term>Amides</term>
<term>Antiviral Agents</term>
<term>Pyrazines</term>
<term>Ribonucleosides</term>
</keywords>
<keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>AMP</term>
<term>Alanine</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>ARN viral</term>
<term>Protéines virales non structurales</term>
</keywords>
<keywords scheme="MESH" qualifier="composition chimique" xml:lang="fr"><term>AMP</term>
<term>Alanine</term>
<term>Amides</term>
<term>Antiviraux</term>
<term>Pyrazines</term>
<term>Ribonucléosides</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Betacoronavirus</term>
<term>Virus Replication</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Betacoronavirus</term>
<term>Réplication virale</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>ARN viral</term>
<term>Betacoronavirus</term>
<term>Protéines virales non structurales</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Molecular Targeted Therapy</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>ARN viral</term>
<term>Protéines virales non structurales</term>
</keywords>
<keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Thérapie moléculaire ciblée</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>AMP</term>
<term>Alanine</term>
<term>Amides</term>
<term>Antiviraux</term>
<term>Pyrazines</term>
<term>Ribonucléosides</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Genome, Viral</term>
<term>Humans</term>
<term>Mutation</term>
<term>Pandemics</term>
<term>Severity of Illness Index</term>
<term>Transcription, Genetic</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Génome viral</term>
<term>Humains</term>
<term>Indice de gravité de la maladie</term>
<term>Mutation</term>
<term>Pandémies</term>
<term>Transcription génétique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The coronavirus disease 2019 (COVID-19) that is wreaking havoc on worldwide public health and economies has heightened awareness about the lack of effective antiviral treatments for human coronaviruses (CoVs). Many current antivirals, notably nucleoside analogs (NAs), exert their effect by incorporation into viral genomes and subsequent disruption of viral replication and fidelity. The development of anti-CoV drugs has long been hindered by the capacity of CoVs to proofread and remove mismatched nucleotides during genome replication and transcription. Here, we review the molecular basis of the CoV proofreading complex and evaluate its potential as a drug target. We also consider existing nucleoside analogs and novel genomic techniques as potential anti-CoV therapeutics that could be used individually or in combination to target the proofreading mechanism.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32853546</PMID>
<DateCompleted><Year>2020</Year>
<Month>09</Month>
<Day>14</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>09</Month>
<Day>14</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4164</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>79</Volume>
<Issue>5</Issue>
<PubDate><Year>2020</Year>
<Month>09</Month>
<Day>03</Day>
</PubDate>
</JournalIssue>
<Title>Molecular cell</Title>
<ISOAbbreviation>Mol. Cell</ISOAbbreviation>
</Journal>
<ArticleTitle>Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting.</ArticleTitle>
<Pagination><MedlinePgn>710-727</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S1097-2765(20)30518-9</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.molcel.2020.07.027</ELocationID>
<Abstract><AbstractText>The coronavirus disease 2019 (COVID-19) that is wreaking havoc on worldwide public health and economies has heightened awareness about the lack of effective antiviral treatments for human coronaviruses (CoVs). Many current antivirals, notably nucleoside analogs (NAs), exert their effect by incorporation into viral genomes and subsequent disruption of viral replication and fidelity. The development of anti-CoV drugs has long been hindered by the capacity of CoVs to proofread and remove mismatched nucleotides during genome replication and transcription. Here, we review the molecular basis of the CoV proofreading complex and evaluate its potential as a drug target. We also consider existing nucleoside analogs and novel genomic techniques as potential anti-CoV therapeutics that could be used individually or in combination to target the proofreading mechanism.</AbstractText>
<CopyrightInformation>Copyright © 2020 Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Robson</LastName>
<ForeName>Fran</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>School of Biological Sciences, University of Bristol, Bristol, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Khan</LastName>
<ForeName>Khadija Shahed</ForeName>
<Initials>KS</Initials>
<AffiliationInfo><Affiliation>School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Le</LastName>
<ForeName>Thi Khanh</ForeName>
<Initials>TK</Initials>
<AffiliationInfo><Affiliation>Life Science Department, University of Science and Technology of Hanoi (USTH), Hanoi, Vietnam; Centre de Recherche en Cancérologie de Marseille, CRCM, Inserm UMR1068, CNRS UMR7258, Aix-Marseille University U105, Institut Paoli-Calmettes, Marseille, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Paris</LastName>
<ForeName>Clément</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Centre de Recherche en Cancérologie de Marseille, CRCM, Inserm UMR1068, CNRS UMR7258, Aix-Marseille University U105, Institut Paoli-Calmettes, Marseille, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Demirbag</LastName>
<ForeName>Sinem</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Faculty of Engineering and Natural Sciences, Sabanci University, İstanbul, Turkey.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Barfuss</LastName>
<ForeName>Peter</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Université Paris-Est, Cermics (ENPC), INRIA, 77455 Marne-la-Vallée, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Rocchi</LastName>
<ForeName>Palma</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Centre de Recherche en Cancérologie de Marseille, CRCM, Inserm UMR1068, CNRS UMR7258, Aix-Marseille University U105, Institut Paoli-Calmettes, Marseille, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ng</LastName>
<ForeName>Wai-Lung</ForeName>
<Initials>WL</Initials>
<AffiliationInfo><Affiliation>School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong. Electronic address: billyng@cuhk.edu.hk.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>08</Month>
<Day>04</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Mol Cell</MedlineTA>
<NlmUniqueID>9802571</NlmUniqueID>
<ISSNLinking>1097-2765</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000577">Amides</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C000656703">EIDD-2801</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011719">Pyrazines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012263">Ribonucleosides</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017361">Viral Nonstructural Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>3QKI37EEHE</RegistryNumber>
<NameOfSubstance UI="C000606551">remdesivir</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>415SHH325A</RegistryNumber>
<NameOfSubstance UI="D000249">Adenosine Monophosphate</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EW5GL2X7E0</RegistryNumber>
<NameOfSubstance UI="C462182">favipiravir</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>OF5P57N2ZX</RegistryNumber>
<NameOfSubstance UI="D000409">Alanine</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName>
<SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000249" MajorTopicYN="N">Adenosine Monophosphate</DescriptorName>
<QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000409" MajorTopicYN="N">Alanine</DescriptorName>
<QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000577" MajorTopicYN="N">Amides</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016679" MajorTopicYN="Y">Genome, Viral</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058990" MajorTopicYN="N">Molecular Targeted Therapy</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011719" MajorTopicYN="N">Pyrazines</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012263" MajorTopicYN="N">Ribonucleosides</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017361" MajorTopicYN="N">Viral Nonstructural Proteins</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">ASO</Keyword>
<Keyword MajorTopicYN="Y">CoV</Keyword>
<Keyword MajorTopicYN="Y">ExoN</Keyword>
<Keyword MajorTopicYN="Y">NA</Keyword>
<Keyword MajorTopicYN="Y">anti-coronavirus drugs</Keyword>
<Keyword MajorTopicYN="Y">antisense oligonucleotide</Keyword>
<Keyword MajorTopicYN="Y">coronavirus</Keyword>
<Keyword MajorTopicYN="Y">exonuclease</Keyword>
<Keyword MajorTopicYN="Y">non-structural protein 14</Keyword>
<Keyword MajorTopicYN="Y">nsp14</Keyword>
<Keyword MajorTopicYN="Y">nucleoside analog</Keyword>
</KeywordList>
<CoiStatement>Declaration of Interests The authors declare no competing interests.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>06</Month>
<Day>09</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2020</Year>
<Month>07</Month>
<Day>24</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>07</Month>
<Day>29</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>8</Month>
<Day>28</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>9</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>8</Month>
<Day>28</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32853546</ArticleId>
<ArticleId IdType="pii">S1097-2765(20)30518-9</ArticleId>
<ArticleId IdType="doi">10.1016/j.molcel.2020.07.027</ArticleId>
<ArticleId IdType="pmc">PMC7402271</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>France</li>
<li>Hong Kong</li>
<li>Royaume-Uni</li>
<li>Turquie</li>
</country>
<region><li>Provence-Alpes-Côte d'Azur</li>
<li>Île-de-France</li>
</region>
<settlement><li>Marne-la-Vallée</li>
<li>Marseille</li>
<li>Sha Tin</li>
</settlement>
<orgName><li>Université chinoise de Hong Kong</li>
</orgName>
</list>
<tree><country name="Royaume-Uni"><noRegion><name sortKey="Robson, Fran" sort="Robson, Fran" uniqKey="Robson F" first="Fran" last="Robson">Fran Robson</name>
</noRegion>
</country>
<country name="Hong Kong"><noRegion><name sortKey="Khan, Khadija Shahed" sort="Khan, Khadija Shahed" uniqKey="Khan K" first="Khadija Shahed" last="Khan">Khadija Shahed Khan</name>
</noRegion>
<name sortKey="Ng, Wai Lung" sort="Ng, Wai Lung" uniqKey="Ng W" first="Wai-Lung" last="Ng">Wai-Lung Ng</name>
</country>
<country name="France"><region name="Provence-Alpes-Côte d'Azur"><name sortKey="Le, Thi Khanh" sort="Le, Thi Khanh" uniqKey="Le T" first="Thi Khanh" last="Le">Thi Khanh Le</name>
</region>
<name sortKey="Barfuss, Peter" sort="Barfuss, Peter" uniqKey="Barfuss P" first="Peter" last="Barfuss">Peter Barfuss</name>
<name sortKey="Paris, Clement" sort="Paris, Clement" uniqKey="Paris C" first="Clément" last="Paris">Clément Paris</name>
<name sortKey="Rocchi, Palma" sort="Rocchi, Palma" uniqKey="Rocchi P" first="Palma" last="Rocchi">Palma Rocchi</name>
</country>
<country name="Turquie"><noRegion><name sortKey="Demirbag, Sinem" sort="Demirbag, Sinem" uniqKey="Demirbag S" first="Sinem" last="Demirbag">Sinem Demirbag</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001236 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001236 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidFranceV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:32853546
   |texte=   Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:32853546" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidFranceV1

This area was generated with Dilib version V0.6.37.
Data generation: Tue Oct 6 23:31:36 2020. Site generation: Fri Feb 12 22:48:37 2021

	Serveur d'exploration sur la COVID en France
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la COVID en France

Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting.

Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki